The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosis

Author： Namaka Mike   Pollitt-Smith Merinda   Gupta Aneri   Klowak Meghann   Vasconcelos Marcus   Turcotte Dana   Gong Yuewen   Melanson Maria  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.22, Iss.2, 2006-02, pp. : 223-239

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging Therapies in Relapsing-Remitting Multiple Sclerosis

By  

Reviews on Recent Clinical Trials, Vol. 5, Iss. 3, 2010-09 ,pp. : 179-188

Bentham Science Publishers

Access to resources Recommend Favorite

Health perceptions and clinical characteristics of relapsing-remitting multiple sclerosis patients: baseline data from an international clinical trial

By Robinson D.   Zhao N.   Gathany T.   Kim L.-L.   Cella D.   Revicki D.  

Current Medical Research and Opinion, Vol. 25, Iss. 5, 2009-05 ,pp. : 1121-1130

Informa Healthcare

Access to resources Recommend Favorite

Clinical Trials in Relapsing-Remitting Multiple Sclerosis /A New Proposal for Dealing with Basic Problems and Restrictions/

By  

Reviews on Recent Clinical Trials, Vol. 6, Iss. 3, 2011-09 ,pp. : 256-258

Bentham Science Publishers

Access to resources Recommend Favorite

Teriflunomide for relapsing remitting multiple sclerosis

By  

PRESCRIBER, Vol. 26, Iss. 18, 2015-09 ,pp. : 11-14

John Wiley & Sons Inc

Access to resources Recommend Favorite

Assessment of new application system in Portuguese patients with relapsing-remitting multiple sclerosis

By de Sá J.   Urbano G.   Reis L.  

Current Medical Research and Opinion, Vol. 26, Iss. 9, 2010-09 ,pp. : 2237-2242

Informa Healthcare

Access to resources Recommend Favorite